Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3516 - Feasibility and barriers to optimal oncological treatment in solid organ transplant patients with de novo cancer


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP


Benoit Rousseau


Annals of Oncology (2017) 28 (suppl_5): v511-v520. 10.1093/annonc/mdx385


B. Rousseau1, A. Jobard1, C. Duvoux2, C. Neuzillet1, P. Compagnon3, D. Azoulay3, A. de la Taille4, L. Salomon4, I. Cholley4, M. Matignon5, P. Grimbert5, C. Tournigand1

Author affiliations

  • 1 Medical Oncology, CHU Henri Mondor, 94000 - Creteil/FR
  • 2 Hepatology, CHU Henri Mondor, 94000 - Creteil/FR
  • 3 Hepatobiliary Surgery And Transplantation, CHU Henri Mondor, 94000 - Creteil/FR
  • 4 Urology, CHU Henri Mondor, 94000 - Creteil/FR
  • 5 Nephrology, CHU Henri Mondor, 94000 - Creteil/FR


Abstract 3516


Transplanted patients (tpts) display higher cancer incidence rates compared to general population. Anti-tumor treatment after transplantation remains scarcely described. This study aimed to report oncological therapy feasibility and outcome in tpts with de novo cancers.


We retrospectively analyzed all consecutive cases of de novo cancer in renal and liver tpts treated in our center. Pts were identified based on systematic research in tpts databases from 2000 to 2016. Pts presenting with non-melanic cutaneous tumors only were excluded. Clinical features, treatments, toxicity and survival data were collected. Active optimal treatment was assessed by comparing treatment that was actually administered with guidelines.


Among 4637 tpts, 209 cases of de novo cancer were identified in 176 (3.8%) pts. Mean age was 52.5+/-11.3 at transplantation and 59+/-10.6 at cancer diagnosis; 122 (69%) were men; 96 (55%) were renal tpts and 80 (45%) liver tpts. At cancer diagnosis, performance status (PS) was 0-1 in 89% (n = 142/160). Tumor type was mainly epithelial (75%, n = 150/200); tumor stage was localized in 80% (n = 163/205) and advanced in 20% (n = 42/205) . Among pts with initially localized tumors, 13% (n = 22/163) had cancer recurrence. Median overall survivals of pts with localized and advanced cancer were of 166 (CI95%: 100.3-ND) and 8.8 (CI95%: 5.0-47.2) months, respectively Among pts with localized tumors, 80% (n = 134/156) received optimal treatment. Reasons for non-optimal treatment were comorbidities in 36% (n = 8/22), risks for the transplant in 36% (n = 8/22), and/or toxicity in 36% (n = 8/22). In contrast, at advanced/recurrent stage, only 36% (n = 19/53) of pts received optimal treatment, and 28% (n = 15/53) best supportive care only. Barriers to optimal treatment were comorbidities in 19% (n = 6/32), risks for the transplant in 22% (n = 7/32), toxicities in 19% (n = 6/32), and poor PS in 33% (n = 17/32).


Oncological treatments are feasible in tpts and survival seems similar to general population. Concerns about the risk of toxicity for the transplanted organ and comorbidities were the main reasons for non-optimal treatment. These observations warrant confirmation in a prospective multicenter study.

Clinical trial identification

Not applicable

Legal entity responsible for the study

CHU Henri Mondor




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.